Fisher Asset Management LLC lowered its stake in Omnicell, Inc. (NASDAQ:OMCL) by 0.0% during the second quarter, Holdings Channel reports. The fund owned 492,202 shares of the company’s stock after selling 112 shares during the period. Fisher Asset Management LLC’s holdings in Omnicell were worth $21,214,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of OMCL. BlackRock Inc. increased its position in Omnicell by 139,475.2% in the first quarter. BlackRock Inc. now owns 4,487,343 shares of the company’s stock valued at $182,412,000 after buying an additional 4,484,128 shares during the last quarter. Vanguard Group Inc. increased its position in Omnicell by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,860,299 shares of the company’s stock valued at $75,622,000 after buying an additional 97,345 shares during the last quarter. Champlain Investment Partners LLC increased its position in Omnicell by 6.2% in the first quarter. Champlain Investment Partners LLC now owns 1,698,140 shares of the company’s stock valued at $69,029,000 after buying an additional 99,075 shares during the last quarter. Conestoga Capital Advisors LLC increased its position in Omnicell by 12.9% in the first quarter. Conestoga Capital Advisors LLC now owns 1,513,866 shares of the company’s stock valued at $61,539,000 after buying an additional 172,642 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Omnicell by 11.0% in the first quarter. Bank of New York Mellon Corp now owns 1,190,691 shares of the company’s stock valued at $48,401,000 after buying an additional 118,201 shares during the last quarter.

Shares of Omnicell, Inc. (NASDAQ OMCL) opened at 42.90 on Monday. The company’s market capitalization is $1.59 billion. Omnicell, Inc. has a 52 week low of $30.35 and a 52 week high of $44.60. The firm’s 50-day moving average is $42.12 and its 200 day moving average is $38.65.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, May 4th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.36. Omnicell had a negative net margin of 1.45% and a positive return on equity of 2.66%. The firm had revenue of $150.90 million for the quarter, compared to analyst estimates of $152.63 million. During the same period last year, the firm earned $0.35 EPS. The business’s quarterly revenue was down 12.3% compared to the same quarter last year. On average, analysts anticipate that Omnicell, Inc. will post $1.28 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/fisher-asset-management-llc-has-21-21-million-position-in-omnicell-inc-omcl/1444789.html.

Several research analysts have recently issued reports on OMCL shares. Cantor Fitzgerald restated an “overweight” rating and set a $47.00 price objective (up previously from $43.00) on shares of Omnicell in a report on Tuesday, June 13th. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. ValuEngine upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $53.00 target price (up previously from $43.00) on shares of Omnicell in a research note on Tuesday, April 25th. Finally, Piper Jaffray Companies cut shares of Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 target price on the stock. in a research note on Friday, April 21st. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Omnicell presently has a consensus rating of “Buy” and a consensus price target of $47.00.

In related news, EVP Dan S. Johnston sold 16,400 shares of Omnicell stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $40.67, for a total transaction of $666,988.00. Following the sale, the executive vice president now directly owns 61,696 shares of the company’s stock, valued at approximately $2,509,176.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Randall A. Lipps sold 9,900 shares of Omnicell stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $43.00, for a total transaction of $425,700.00. Following the sale, the chairman now directly owns 208,982 shares in the company, valued at $8,986,226. The disclosure for this sale can be found here. Over the last three months, insiders sold 101,000 shares of company stock worth $4,221,001. Insiders own 3.75% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.